Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-06-19
2007-06-19
Huff, Sheela J. (Department: 1643)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C530S350000
Reexamination Certificate
active
10677593
ABSTRACT:
There is disclosed a polypeptide (CD30-L) and DNA sequences, vectors and transformed host cells useful in providing CD30-L polypeptides. The CD30-L polypeptide binds to the receptor known as CD30, which is expressed on a number of cell types, among which are Hodgkin's Disease tumor cells, large cell anaplastic lymphoma cells, adult T-cell leukemia (T-ALL) cells, and a number of other malignant cell types. CD30-L polypeptides find use as carriers for delivering diagnostic and cytotoxic agents to cells expressing the CD30 receptor.
REFERENCES:
patent: 5165923 (1992-11-01), Thorpe et al.
patent: 0 412050 (1991-02-01), None
patent: WO 87/07144 (1987-12-01), None
patent: WO 91/07437 (1991-05-01), None
patent: WO 93/10232 (1993-05-01), None
Armitage et al., “Molecular and Biological Characterization of a Murine Ligand for CD40,”Nature 357: 80-82, 1992.
Zsebo et al., “Stem Cell Factor is Encoded at the SI Locus of the Mouse and is the Ligand for the c-kit Tyrosine Kinase Receptor,”Cell 63: 213-224, 1990.
Schwarting et al., “Cluster report: CD30,”Leucocyte Typing IV: White Cell Differentiation Antigens: p. 419-422, Oxford University Press, 1989.
Berenbeck et al., “Detection of soluble Hodgkin-associated CD30 antigen in the sera of patients with Hodgkin's lymphoma,”Leucocyte Typing IV: White Cell Differentiation Antigens: p. 425, Oxford University Press, 1989.
Dallenbach et al., “Soluble CD30 antigen in the sera of patients with adult T-cell lymphoma/leukaemia (ATL): a marker for disease activity,”Leucocyte Typing IV: White Cell Differentiation Antigens: p. 426-428, Oxford University Press, 1989.
Smith et al., “CD30 Antigen, a Marker for Hodgkin's Lymphoma, Is a Receptor Whose Ligand Defines an Emerging Family of Cytokines with Homology to TNF,”Cell 73: 1349-1360, 1993.
Gruss et al., “CD30 Ligand: Molecular Cloning and Pathobiological Role in CD30-Positive Malignant Lymphomas,” presented at Keystone Symposium on B and T Cell Lymphomas, Copper Mountain, CO, Apr. 17-24, 1993.
Loh et al., “Polymerase Chain Reaction with Single-Sided Specificity: Analysis of T Cell Receptor δ Chain,”Science 243: 217-220, 1989.
Falini et al., “Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin,”Lancet 339: 1195-1196, 1992.
da Costa et al., “Immunoscintigraphy in Hodgkin's disease and anaplastic large cell lymphomas: Results in 18 patients using the iodine radiolabeled monoclonal antibody HRS-3,”Ann. Onc. 3(Suppl. 4): S53-S57, 1992.
Engert et al., “Evaluation of Ricin A Chain-containing Immunotoxins Directed against the CD30 Antigen as Potential Reagents for the Treatment of Hodgkin's Disease,”Cancer Res. 50: 84-88, 1990.
Engert et al., “Experimental therapy in Hodgkin's disease,”Ann. Onc. 3(Supp. 4): S97-S100, 1992.
Stein et al., “Three new lymphoid activation antigens,”Leucocyte Typing III: White Cell Differentiation Antigens, p. 574, Oxford University Press, 1987.
Schwarting et al., “BER-H2: a new monoclonal antibody of the Ki-1 family for the detection of Hodgkin's disease in formaldehyde-fixed tissue sections,”Leucocyte Typing III: White Cell Differentiation Antigens, pp. 574-575, Oxford University Press, 1987.
Newcom et al., “The Role of Ki-1 Antigen in the Autocrine TGFβ Growth Regulation of Reed-Sternberg Cells, Ki-1 Lymphoma Cells, and Activated Thymocytes,”Blood 80(10)Supp. 1: 305a, abstract No. 1211, Nov. 15, 1992.
Wu et al., “EBV and Tumor Progression to Ki-1 Anaplastic Large Cell Lymphoma (ALCL),”Blood 80(10)Supp. 1: 445a Abstract No. 1771, Nov. 15, 1992.
Goodwin et al., “The TNF/NGF Superfamily of Receptors and Their Ligands,”J. Cell. Biochem., Keystone Symposia on Molecular & Cellular Biology, Suppl. 17B, abstract F0202, Jan. 26-Feb. 10, 1993.
Pallesen and Hamilton-Dutoit, “Ki-1 (CD-30) Antigen is Regularly Expressed by Tumor Cells of Embryonal Carcinoma,”Am. J. Path. 133(3): 446-450, 1988.
Schwarting et al., “BER-H2: A New Anti-Ki-1 (CD30) Monoclonal Antibody Directed at a Formol-Resistant Epitope,”Blood 74: 1678-1689, 1989.
Andreesen et al., “Human Macrophages Can Express the Hodgkin's Cell- Associated Antigen Ki-1 (CD30),”Am. J. Path. 134: 187-192, 1989.
Mechtersheimer and Möller, “Expression of Ki-1 Antigen (CD30) in Mesenchymal Tumors,”Cancer 66(8): 1732-1737. 1990.
Gianotti et al., “Primary Cutaneous Pleomorphic T-Cell Lymphoma Expressing CD30 Antigen,”Am. J. Dermatopath. 13(5): 503-508, 1991.
Burns and Dardick, “Ki-1 Positive Non-Hodgkin's Lymphomas,”Am. J. Clin. Path. 93(3): 327-332, 1990.
Piris et al., “CD30 expression in non-Hodgkin's lymphoma,”Histopath. 17: 211-218, 1990.
Miettinen, “CD30 Distribution,”Arch. Pathol. Lab. Med. 116: 1197-1201, 1992.
Piris et al., “CD30 expression in follicular lymphoma,”Histopath. 18: 25-29, 1991.
Maeda and Takahashi, “Characterization of skin infiltrating cells in adult T-cell leukaemia/lymphoma (ATLL): clinical, histological and immunohistochemical studies on eight cases,”Brit. J. Derm. 121: 603-612, 1989.
Eckert et al., “Follicular Lymphoid Hyperplasia of the Skin with High Content of Ki-1 Positive Lymphocytes,”Am. J. Dermatopath. 11(4): 345-352, 1989.
Aruffo and Seed, “Molecular Cloning of a CD28 cDNA by a High Efficiency COS Cell Expression System,”Proc. Nat. Acad. Sci. USA 84: 8573-8577, 1987.
Flanagan and Leder, “ThekitLigand: A Cell Surface Molecule Altered in Steel Mutant Fibroblasts,”Cell 63: 185-194, 1990.
Josimovic-Alasevic et al., “Ki-1 (CD30) Antigen is Released by Ki-1 Positive Tumor Cellsin vitroandin vivo,” Eur. J. Immunol. 19: 157-162, 1989.
Froese et al., “Biochemical Characterization and Biosynthesis of the Ki-1 Antigen in Hodgkin-Derived and Virus-Transformed Human B and T Lymphoid Cell Lines,”J. Immunol. 139(6): 2081-2087, 1987.
Shohat et al., “Inhibition of Cell Growth Mediated by Plasmids Encoding p53 Antisense,”Oncogene 1: 277-283, 1987.
Riordan and Martin, “Oligonucleotide-based Therapeutics,”Nature 350: 442-443, 1991.
Pfreundschuh et al., “In-vivo-Imaging von Hodgkin-Lymphomen mit monoklonalen Antikörpern,”Onkologie 12: Supp. 1, 30-33, 1989.
Carde et al., “Immunoscintigraphy of Hodgkin's Disease: In Vivo use of Radiolabelled Monoclonal Antibodies Derived from Hodgkin Cell Lines,”Eur. J. Cancer 26(4): 474-479, 1990.
Stein et al., “The Expression of the Hodgkin's Disease Associated Antigen Ki-1 in Reactive and Neoplastic Lymphoid Tissue: Evidence that Reed-Sternberg Cells and Histiocytic Malignancies Are Derived from Activated Lymphoid Cells,”Blood 66(4): 848-853, 1985.
Andreesen, et al., “A Hodgkin Cell-Specific Antigen is Expressed on a Subset of Auto-and Alloactivated T (Helper) Lymphoblasts,”Blood 63(6): 1299-1302, 1984.
Klein, “Epstein-Barr Virus-Carrying Cells in Hodgkin's Disease,”Blood 80(2): 299-301, 1992.
Poiesz, et al., “Detection and isolation of type C retrovirus particles from fresh and cultured lumphocytes of a patient with cutaneous T-cell lymphoma,”Proc. Natl. Acad. Sci. USA 77(12): 7415-7419, 1980.
Schwab et al., “Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells,”Nature 299: 65-67, 1982.
Stein et al., “Identification of Hodgkin and Sternberg-Reed Cells as a Unique Cell Type Derived from a Newly Detected Small-Cell Population,”Intl. J. Cancer 30: 445-459, 1982.
Durkop et al., “Molecular Cloning and Expression of a New Member of the Nerve Growth Factor Receptor Family that is Characteristic for Hodgkin's Disease,”Cell 68: 421-427, 1992.
Capon et al., “Designing CD4 Immu
Armitage Richard J.
Goodwin Raymond G.
Smith Craig A.
Huff Sheela J.
Immunex Corporation
Lingenfelter Susan E.
Perkins Patricia Anne
LandOfFree
CD30 ligand does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with CD30 ligand, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CD30 ligand will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3857790